A clinical trial led by researchers from Hospital Clínic de Barcelona, the August Pi i Sunyer Biomedical Research Institute ...

Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.

A new review published in Calcified Tissue International highlights major advances in understanding and preventing bone loss ...

Conditions like depression may not only be complications of this rheumatoid arthritis, but may also be involved in the progression of this disease, new evidence suggests.

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory ...

Strong initial responses in 4 of 6 patients after many standard drugs had failed ...

Whether you are seeking information for yourself or a loved one, read on to learn more about the disease and how to better understand its signs and symptoms. Rheumatoid arthritis is an inflammatory ...

A promising new study suggests rheumatoid arthritis may not be as inevitable as once thought for people at high risk.

Rheumatoid arthritis-associated interstitial lung disease (ILD) presents a paradox: it is common and a major cause of ...

Managing symptoms of rheumatoid arthritis may require trying different medicines to see what works best for you and your symptoms. The approval of Xeljanz has led to changes in how rheumatoid ...

A multimillion dollar research mission could turn the tide on a condition so common it affects more Australians than the ...